Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Apyx Medical Corporation specializes in advanced energy-based surgical devices, particularly in the fields of cosmetic and reconstructive surgery. Its flagship product, the Renuvion® system, utilizes helium plasma technology, providing a unique competitive edge in minimally invasive procedures. The company primarily operates in the United States but is expanding its presence in international markets.
Apyx generates revenue through the sale of its proprietary Renuvion® system and related consumables, capitalizing on the growing demand for minimally invasive surgical procedures. The company benefits from a strong pricing power due to its innovative technology and established brand recognition in the aesthetic surgery market.
Regulatory approvals for new products or indications
Market adoption rates of Renuvion® in cosmetic procedures
Expansion into international markets
Partnerships or collaborations with other medical device companies
Regulatory changes affecting medical device approvals
Technological disruption from competitors developing superior products
Emerging competitors with innovative surgical technologies
Price competition from established medical device manufacturers
High debt-to-equity ratio of 3.08 raises concerns about financial stability
Negative operating cash flow may limit operational flexibility
moderate - The demand for elective surgical procedures is somewhat correlated with consumer spending and economic conditions, which can affect revenue.
Low - Apyx's business model is not heavily reliant on debt financing, but higher rates could impact consumer spending on elective procedures.
minimal
growth - Investors are likely attracted to Apyx for its potential in the expanding market for minimally invasive procedures.
high - The stock has shown significant volatility with a 1-year return of 100%.